Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy

• Үндсэн зохиолчид: Claudia Arndt (Зохиогч), Antje Tunger (Зохиогч), Rebekka Wehner (Зохиогч), Rebecca Rothe (Зохиогч), Eleni Kourtellari (Зохиогч), Stephanie Luttosch (Зохиогч), Katharina Hannemann (Зохиогч), Stefanie Koristka (Зохиогч), Liliana R. Loureiro (Зохиогч), Anja Feldmann (Зохиогч), Torsten Tonn (Зохиогч), Theresa Link (Зохиогч), Jan Dominik Kuhlmann (Зохиогч), Pauline Wimberger (Зохиогч), Michael Philipp Bachmann (Зохиогч), Marc Schmitz (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Frontiers Media S.A., 2023-02-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib is an emerging cancer therapeutic that just recently gained Food and Drug Administration approval for treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor (Her)2-negative breast cancer in combination w...